AIM: To evaluate the anatomic parameters, visual function and quality of life(QOL)in patients with age-related macular degeneration(ARMD)who were transferred from Ranibizumab to Conbercept.

METHODS: Twenty patients(29 eyes)with angiogenic ARMD who were treated in our hospital in January 2016 to August 2017 because of the poor therapeutic effect of ranibizumab were selected. The main outcome measures were BCVA, contrast sensitivity(CS), mean changes of central retinal thickness(CRT)and 25 visual function questionnaires(NEI VFQ-25)from baseline to 4mo. The statistical data were analyzed by paired t test to compare the mean values of continuous variables.

RESULTS: At 4mo after treatment, BCVA were significantly improved compared to before treatment(P<0.05). The CRT detected by OCT decreased(P<0.05). CS at different frequency was better than before treatment(P<0.05). NEI VFQ-25 scores were higher than before treatment(P<0.05).

CONCLUSION: In the treatment of age-related macular degeneration with conbercept, the visual function and the quality of life are remarkably improved.